WallStSmart
BIO-

Bio-Rad Laboratories Inc

NYSE: BIO-B · HEALTHCARE · MEDICAL DEVICES

$309.37
+0.00% today

Updated 2026-07-30

Market cap
$8.28B
P/E ratio
51.56
P/S ratio
3.20x
EPS (TTM)
$6.00
Dividend yield
52W range
$245 – $321
Volume
0.0M

WallStSmart proprietary scores

41
out of 100
Grade: D
Sell
Investment rating
2.7
Growth
F
8.5
Quality
A
4.5
Profitability
C
4.3
Valuation
C
3/9
Piotroski F-Score
Weak
3.4
Altman Z-Score
Safe zone
Industry rank
View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target
12-Month target
Intrinsic (DCF)
Margin of safety

Price chart

Stock snapshot

Strengths
+ Altman Z 3.36 — safe zone
+ Free cash flow $78.10M — positive
+ Debt/equity 0.20x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- P/E 51.56x — expensive valuation

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$2.80B$2.67B$2.57B$2.58B$2.59B
Net income$-3.63B$-637.32M$-1.84B$759.90M$-527.10M
EPS$6.00
Free cash flow$80.29M$218.26M$266.20M$374.60M$78.10M
Profit margin-129.45%-23.86%-71.86%29.42%6.52%

Recent insider activity

DateInsiderTypeSharesPrice
2026-05-11ENGELHARDT, EVA ANETTESale550$246.54
2026-04-24LAKKARAJU, ROOP KALYANSale1,078
2026-04-24LAKKARAJU, ROOP KALYANBuy1,078

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
BIO-B$8.28B412.74.54.38.5Hold
LLY$1.02T7610.010.04.36.0Strong Buy
JNJ$615.36B574.78.54.36.0Buy
ABBV$447.53B634.08.04.75.0-78.83%Buy
UNH$391.69B627.35.54.06.0-30.51%Buy
MRK$307.25B503.38.02.75.0-62.28%Hold

Smart narrative

Bio-Rad Laboratories Inc trades at $309.37. representing a P/E of 51.56x trailing earnings. Our Smart Value Score of 41/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.36, it sits in the safe zone. TTM revenue stands at $2.59B. with profit margins at 6.52%.

Frequently asked questions

What is Bio-Rad Laboratories Inc's stock price?

Bio-Rad Laboratories Inc (BIO-B) trades at $309.37, on a P/E of 51.6x and a P/S of 3.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.

Is Bio-Rad Laboratories Inc overvalued?

Bio-Rad Laboratories Inc carries a Smart Value Score of 41/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.

What is Bio-Rad Laboratories Inc's revenue?

Bio-Rad Laboratories Inc's trailing twelve-month revenue is $2.59B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.

Altman Z-Score?

Bio-Rad Laboratories Inc's Altman Z-Score is 3.36, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD

Quick metrics

P/S ratio3.20x
ROE2.46%
Beta1.09
50D MA$293.71
200D MA$293.76
Shares out0.01B
Float0.02B
Short ratio
Avg volume0.0M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years